Los Angeles Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $60.9M | Sell |
78,880
-21,628
| -22% | -$16.6M | 0.24% | 93 |
|
|
2025
Q4 | $65.7M | Buy |
100,508
+5,173
| +5% | +$3.51M | 0.22% | 82 |
|
|
2025
Q3 | $53.6M | Buy |
95,335
+87,926
| +1,187% | +$49.7M | 0.18% | 103 |
|
|
2025
Q2 | $3.89M | Sell |
7,409
-356
| -5% | -$199K | 0.01% | 342 |
|
|
2025
Q1 | $4.92M | Buy |
7,765
+7,239
| +1,376% | +$4.98M | 0.02% | 297 |
|
|
2024
Q4 | $375K | Sell |
526
-1,234
| -70% | -$1.04M | ﹤0.01% | 883 |
|
|
2024
Q3 | $1.85M | Sell |
1,760
-773
| -31% | -$860K | 0.01% | 477 |
|
|
2024
Q2 | $2.66M | Buy |
2,533
+1,290
| +104% | +$1.25M | 0.01% | 391 |
|
|
2024
Q1 | $1.2M | Sell |
1,243
-4,102
| -77% | -$3.9M | ﹤0.01% | 638 |
|
|
2023
Q4 | $4.69M | Buy |
5,345
+4,645
| +664% | +$3.83M | 0.02% | 341 |
|
|
2023
Q3 | $576K | Buy |
700
+147
| +27% | +$116K | ﹤0.01% | 783 |
|
|
2023
Q2 | $397K | Sell |
553
-38,693
| -99% | -$29.8M | ﹤0.01% | 923 |
|
|
2023
Q1 | $32.2M | Sell |
39,246
-5,027
| -11% | -$3.79M | 0.14% | 150 |
|
|
2022
Q4 | $31.9M | Sell |
44,273
-9,786
| -18% | -$7.22M | 0.16% | 141 |
|
|
2022
Q3 | $37.2M | Sell |
54,059
-3,260
| -6% | -$2.05M | 0.19% | 124 |
|
|
2022
Q2 | $33.9M | Buy |
57,319
+1,144
| +2% | +$744K | 0.17% | 132 |
|
|
2022
Q1 | $39.2M | Sell |
56,175
-54,720
| -49% | -$34.6M | 0.15% | 125 |
|
|
2021
Q4 | $70M | Buy |
110,895
+77,100
| +228% | +$47.4M | 0.26% | 86 |
|
|
2021
Q3 | $20.5M | Sell |
33,795
-10,402
| -24% | -$6.46M | 0.09% | 187 |
|
|
2021
Q2 | $24.7M | Buy |
44,197
+18,553
| +72% | +$9.4M | 0.11% | 173 |
|
|
2021
Q1 | $12.1M | Buy |
25,644
+22,111
| +626% | +$10.8M | 0.05% | 272 |
|
|
2020
Q4 | $1.71M | Sell |
3,533
-7,300
| -67% | -$3.94M | 0.01% | 715 |
|
|
2020
Q3 | $6.06M | Sell |
10,833
-4,748
| -30% | -$2.88M | 0.03% | 329 |
|
|
2020
Q2 | $9.72M | Sell |
15,581
-11,028
| -41% | -$6.26M | 0.05% | 278 |
|
|
2020
Q1 | $13M | Sell |
26,609
-500
| -2% | -$206K | 0.08% | 208 |
|
|
2019
Q4 | $10.2M | Buy |
27,109
+12,650
| +87% | +$4.26M | 0.05% | 282 |
|
|
2019
Q3 | $4.01M | Sell |
14,459
-3,310
| -19% | -$979K | 0.02% | 469 |
|
|
2019
Q2 | $5.56M | Sell |
17,769
-2,804
| -14% | -$934K | 0.03% | 423 |
|
|
2019
Q1 | $8.45M | Sell |
20,573
-54,179
| -72% | -$22.3M | 0.05% | 340 |
|
|
2018
Q4 | $27.9M | Sell |
74,752
-2,128
| -3% | -$779K | 0.17% | 141 |
|
|
2018
Q3 | $31.1M | Sell |
76,880
-10,318
| -12% | -$3.93M | 0.16% | 156 |
|
|
2018
Q2 | $30.1M | Sell |
87,198
-20,234
| -19% | -$6.33M | 0.17% | 155 |
|
|
2018
Q1 | $37M | Buy |
107,432
+16,290
| +18% | +$5.67M | 0.21% | 126 |
|
|
2017
Q4 | $34.3M | Buy |
91,142
+70,307
| +337% | +$28.5M | 0.19% | 143 |
|
|
2017
Q3 | $9.32M | Buy |
20,835
+16,854
| +423% | +$8.02M | 0.05% | 326 |
|
|
2017
Q2 | $1.96M | Sell |
3,981
-1,746
| -30% | -$764K | 0.01% | 615 |
|
|
2017
Q1 | $2.22M | Buy |
5,727
+4,659
| +436% | +$1.73M | 0.02% | 549 |
|
|
2016
Q4 | $392K | Hold |
1,068
| – | – | ﹤0.01% | 954 |
|
|
2016
Q3 | $429K | Sell |
1,068
-128
| -11% | -$51.3K | ﹤0.01% | 964 |
|
|
2016
Q2 | $418K | Sell |
1,196
-100
| -8% | -$38.5K | ﹤0.01% | 963 |
|
|
2016
Q1 | $467K | Sell |
1,296
-56,035
| -98% | -$23.1M | ﹤0.01% | 834 |
|
|
2015
Q4 | $31.1M | Sell |
57,331
-484
| -0.8% | -$262K | 0.28% | 97 |
|
|
2015
Q3 | $26.9M | Sell |
57,815
-2,005
| -3% | -$1.08M | 0.26% | 109 |
|
|
2015
Q2 | $30.5M | Sell |
59,820
-39,720
| -40% | -$19.4M | 0.28% | 106 |
|
|
2015
Q1 | $44.9M | Buy |
99,540
+31,513
| +46% | +$13.4M | 0.41% | 66 |
|
|
2014
Q4 | $27.9M | Buy |
68,027
+53,162
| +358% | +$20.9M | 0.26% | 109 |
|
|
2014
Q3 | $5.36M | Buy |
14,865
+14,068
| +1,765% | +$4.72M | 0.06% | 281 |
|
|
2014
Q2 | $225K | Sell |
797
-23,452
| -97% | -$6.95M | ﹤0.01% | 1111 |
|
|
2014
Q1 | $7.28M | Buy |
+24,249
| New | +$7.47M | 0.08% | 274 |
|
Other funds holding REGN
VCM
N
Los Angeles Capital Management's REGN Position: Q1 2026 in Review
Los Angeles Capital Management reduced its Regeneron Pharmaceuticals (REGN) stake by 22% in Q1 2026, selling an estimated $16.6M and leaving 78,880 shares worth $60.9M. The position accounts for 0.24% of the portfolio, ranked #93.
Los Angeles Capital Management first reported a position in REGN in Q1 2014 and has held it in 49 quarters since. The position peaked at $70M in Q4 2021. 1,396 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Los Angeles Capital Management held 78,880 shares of Regeneron Pharmaceuticals worth $60.9M as of Q1 2026.
- Los Angeles Capital Management sold 21,628 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $16.6M.
- Regeneron Pharmaceuticals made up 0.24% of Los Angeles Capital Management's portfolio in Q1 2026, its #93 holding.
- Los Angeles Capital Management first reported a position in Regeneron Pharmaceuticals in Q1 2014 and has held it in 49 quarters since.
- Los Angeles Capital Management's Regeneron Pharmaceuticals position peaked at $70M in Q4 2021.
- 1,396 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.